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Dear Editor, atopic eczema is one of the most burdensome skin diseases across the globe1 and affects 1 
up to 20% of children in the UK. The mainstay of treatment is regular use of emollients2 including 2 
leave-on emollients, soap substitutes and emollient bath additives. However, the lack of evidence to 3 
support the use of bath additives has led some to question their role in atopic eczema management3. 4 
A recently published, independent, randomised controlled trial has provided robust evidence that 5 
bath emollients provide no meaningful benefit in addition to standard care (regular use of leave-on 6 
emollients and avoidance of soap)4. 7 
The aim of this study was to examine the proportion of children in England with atopic eczema who 8 
are currently prescribed bath emollients in primary care, and to describe how this proportion varies 9 
according to socio-demographic factors. 10 
Pseudonymised primary care data from the Hospital Episode Statistics-linked Clinical Practice 11 
Research Datalink (HES-linked CPRD) were used to conduct this cross-sectional observational study. A 12 
cohort of children with atopic eczema was identified from the CPRD dataset5 defined using validated 13 
diagnostic criteria6. From this initial cohort, only children with active eczema were included in the 14 
study, defined as those given either a diagnosis of eczema or an eczema-related treatment between 15 
1st April 2014 and 31st March 2015.  Age, gender, ethnicity, and socioeconomic deprivation (measured 16 
using quintiles of the English Index of Multiple Deprivation) were extracted. Since the quality of 17 
ethnicity data in the HES-linked CPRD population is only comparable to Office for National Statistics 18 
data for those registered with their GPs after 1st January 20067, we excluded children registered before 19 
this date and thus the eldest child was aged 9 by the study end date. Disease severity was estimated 20 
based on the overall potency of treatments prescribed, broadly following the stepped approach 21 
recommended by the National Institute of Health and Care Excellence (NICE)2. In brief, those receiving 22 
only emollients were classed as having very mild eczema, while those receiving potent topical steroids 23 
or referred to a dermatologist were deemed to have severe eczema.  24 
Emollient prescriptions issued to our cohort within the study dates were classified as either “leave-25 
on” or “bath emollients.”  We calculated the proportion of children prescribed each emollient type 26 
and compared the proportion across different socio-demographic groups using logistic regression to 27 
generate odds ratios (OR) and 95% confidence intervals (CI).  28 
A total of 13,618 children with active eczema were identified: 54% male, 75% white ethnicity with 29 
proportionally more younger children (36% <2 years, 40% 3-5 years and 25% 6-9 years).  30 
We found that 34% of children with active atopic eczema were prescribed a bath emollient by their 31 
GP during the one-year study period (29% received both bath and leave-on emollients and 5% received 32 
a bath emollient without a leave-on emollient). Overall, 75% of children received a leave-on emollient 33 
and 20% received neither a leave-on nor a bath emollient. 34 
Age had the greatest impact on prescription rates of bath emollients. Children aged ≤2 years-old were 35 
nearly twice as likely to receive bath emollients as those aged 6-9 (43% vs 24%, OR=0.41, 95% CI 0.37-36 
0.45, Figure 1). This may be reflective of older children being more likely to shower than bathe.  37 
Those most socioeconomically deprived were more likely to be prescribed bath emollients than those 38 
least deprived (37% vs 29% OR=1.40, 95% CI 1.25-1.56). One possible explanation is that those less 39 
deprived are purchasing their emollients over-the-counter, which are not counted in this study.  40 
We found no meaningful differences in prescription rates according to disease severity, gender, or 41 
ethnic group. 42 
The strengths of this study lie in the large sample size, allowing us to obtain accurate estimates at a 1 
population level8. However, we could not account for emollients purchased over-the-counter or 2 
shared amongst family members. Further, this study only assessed whether emollients were 3 
prescribed at all; it did not examine the quantity or frequency of prescriptions. 4 
In conclusion, one-third of children in England with atopic eczema were prescribed emollient bath 5 
additives. Since recent evidence suggests that bath emollients provide little benefit in the 6 
management of eczema in addition to standard management4, this study highlights an area for 7 
possible reinvestment in more cost-effective treatments, such as leave-on emollients. It is concerning 8 
that up to 25% of children may be receiving sub-optimal emollient therapy: either no emollient at all, 9 
or bath emollients prescribed without concurrent leave-on emollients. Care should be taken to ensure 10 
that children have access to adequate quantities of leave-on emollients and soap substitutes, which 11 
remain the mainstay of treatment for atopic eczema.  12 
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